Electromed, Inc. has announced its financial results for the third quarter of fiscal year 2025, showing a strong performance marked by growth in key financial metrics. The company's net revenue increased by 13.1% to $15.7 million, compared to $13.9 million in the same quarter of the previous fiscal year. This growth was significantly driven by a 14.8% year-over-year increase in revenue from the direct homecare business, which achieved $14.1 million, up from $12.3 million. The rise in revenues was attributed to more referrals and approvals, improved sales force efficiency, and increased net revenues per approval. Operating income for the quarter rose to $2.1 million, marking a 16.2% increase from the previous year's third quarter. Net income also saw a substantial rise of 26.7%, reaching $1.9 million, or $0.21 per diluted share, compared to $1.5 million, or $0.17 per diluted share, in the prior year. Additionally, Electromed's board of directors approved a $5 million stock repurchase authorization during this quarter. The company also reported an increase in operating cash flow, which reached $7.5 million for the nine months ending in the third quarter of fiscal year 2025, up by $3.0 million from the same period last year. As of March 31, 2025, Electromed had $15.2 million in cash.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。